| 李立群,杨晓军,全 赢,等.吉西他滨化疗联合PD-1/PD-L1阻断治疗胰腺导管腺癌的研究进展[J].肿瘤学杂志,2023,29(11):928-933. |
| 吉西他滨化疗联合PD-1/PD-L1阻断治疗胰腺导管腺癌的研究进展 |
| Research Progress on Gemcitabine Chemotherapy Combined with PD-1/PD-L1 Inhibitors for Pancreatic Ductal Adenocarcinoma |
| 投稿时间：2023-04-29 |
| DOI：10.11735/j.issn.1671-170X.2023.11.B006 |
|
 |
| 中文关键词: 胰腺导管腺癌 肿瘤微环境 调节性T淋巴细胞 肿瘤相关巨噬细胞 免疫疗法 化学疗法 |
| 英文关键词:pancreatic ductal adenocarcinoma tumor microenvironment regulatory T-lymphocytes tumor-associated macrophages immunotherapy chemotherapy |
| 基金项目:甘肃省创新基地和人才项目资助（20JR10RA433）；甘肃省省级科技计划重点研发项目（21YF5WA027）；国家卫健委胃肠肿瘤诊治重点实验室2022年度硕博士/博士后基金项目（NHCDP2022001）；甘肃省人民医院博士研究生导师培育项目（22GSSYA-3） |
|
| 摘要点击次数: 299 |
| 全文下载次数: 197 |
| 中文摘要: |
| 摘 要：胰腺导管腺癌（pancreatic ductal adenocarcinoma，PDAC）不仅对于PD-1/PD-L1阻断剂单药治疗无效，而且对于常用的吉西他滨化疗也产生了耐药性，原因可能是PDAC具有独特的肿瘤微环境。目前，已有相关研究报道吉西他滨加抗PD-1抗体治疗延长了PDAC肝转移小鼠模型的生存期。全文综述PDAC对吉西他滨治疗产生耐药性的机制，并且探讨了抗PD-1/PD-L1抗体联合吉西他滨治疗PDAC可改善患者生存期的可能性。 |
| 英文摘要: |
| Abstract： Pancreatic ductal adenocarcinoma(PDAC) is usually resistant to PD-1/PD-L1 inhibitor monotherapy， as well as to gemcitabine chemotherapy， probably due to the unique tumor microenvironment of PDAC. Recent studies have shown that PD-1/PD-L1 inhibitors administrated with gemcitabine may prolong the survival of PDAC-bearing mice with liver metastasis， which brought new clue for clinical study. This paper reviews the mechanisms of PDAC resistant to PD-1/PD-L1 inhibitors and gemcitabine therapy， also explores the possibility of the combination of PD-1/PD-L1 inhibitors and gemcitabine for increasing treatment efficacy and improving survival of PDAC patients. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |